Table 4.

Univariate analyses of determining factors that affect VTE development in patients with lymphoid malignancies

Factor	Univariate analysis
	Odds ratio (95% CI), P
Male gender	0.65 (0.38–1.12), 0.1208
Age	1.00 (0.98–1.11), 0.9610
Type of lymphoma: DLBCL	2.03 (1.14–3.61), 0.0157
Advanced diseasea	1.61 (0.94–2.77), 0.0844
Poor prognostic diseaseb	0.54 (0.31–0.92), 0.0224
Constitutional symptoms	0.90 (0.52–1.55), 0.6940
Bulky disease	4.34 (2.21–8.53), 0.0001
High KRSc	1.06 (0.51–2.21), 0.8770
Pre-chemotherapy platelet count > 350 × 109/l	1.15 (0.63–2.12), 0.6495
Pre-chemotherapy leukocyte count > 11 × 109/l	1.81 (1.01–3.26), 0.0474
Pre-chemotherapy hemoglobin < 10 g/dl × 109/l	0.48 (0.23–1.01), 0.0526

CI confidence interval, IPI International Prognostic Index

P < 0.05: statistically significant

^aAdvanced disease: stage according to Lugano IV

^bIPI, International Prognostic Index ≥ 3; IPS, International Prognostic Score ≥ 3

^cAccording to the Khorana Risk Score (KRS) for VTE risk assessment